Skip to content

Clinical trials

Phase 2 Anemia, Refractory trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anemia, Refractory Phase: Phase 2 Clear all

56 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20017
20021
20034
20041
20056
20064
20073
20081
20092
20101
20112
20131
20151
20181
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed42
Terminated8
Unknown status4
Recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center8
Roswell Park Cancer Institute4
H. Lee Moffitt Cancer Center and Research Institute3
Masonic Cancer Center, University of Minnesota3
National Cancer Institute (NCI)3
Wake Forest University Health Sciences3
Alliance for Clinical Trials in Oncology2
Case Comprehensive Cancer Center2
European Organisation for Research and Treatment of Cancer - EORTC2
Memorial Sloan Kettering Cancer Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anemia, Refractory56
Myelodysplastic Syndromes48
Anemia, Refractory, with Excess of Blasts47
Leukemia36
Leukemia, Myelomonocytic, Chronic31
Myeloproliferative Disorders24
Leukemia, Myeloid, Acute22
Precursor Cell Lymphoblastic Leukemia-Lymphoma22
Leukemia, Myeloid, Chronic-Phase17
Myelodysplastic-Myeloproliferative Diseases17

Trials

Showing 26 to 50 of 56. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.